- Report
- October 2023
- 190 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Report
- October 2023
- 180 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Report
- February 2024
- 184 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Drug Pipelines
- January 2024
- 70 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- May 2023
- 220 Pages
Global
From €3399EUR$3,500USD£2,933GBP
- Report
- June 2023
- 175 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- February 2024
- 114 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- July 2023
- 115 Pages
Global
From €4371EUR$4,500USD£3,770GBP
- Report
- June 2023
- 113 Pages
Global
From €4371EUR$4,500USD£3,770GBP
- Report
- January 2024
- 200 Pages
Global
From €4031EUR$4,150USD£3,477GBP
- Report
- November 2022
- 190 Pages
Global
From €4661EUR$4,799USD£4,021GBP
- Report
- March 2023
- 174 Pages
Global
From €1844EUR$1,899USD£1,591GBP
- Report
- May 2022
- 467 Pages
Global
From €4661EUR$4,799USD£4,021GBP
- Report
- October 2019
- 380 Pages
Global
From €4370EUR$4,499USD£3,770GBP
- Report
- May 2018
- 140 Pages
Global
From €3399EUR$3,500USD£2,933GBP
- Report
- March 2023
- 76 Pages
Global
From €1360EUR$1,400USD£1,173GBP
- Report
- March 2022
- 109 Pages
Global
From €738EUR$760USD£637GBP
€923EUR$950USD£796GBP
- Report
- November 2021
- 40 Pages
Global
From €4808EUR$4,950USD£4,147GBP
- Report
- May 2018
- 15 Pages
Global
- Report
- June 2021
Global
From €3885EUR$4,000USD£3,351GBP
RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more